Telix QSAM Inc (QSAM)

[AXNMAN]

Investors are always looking for the next great bioscience company that seeks effective treatment in the ongoing battle against cancer and related diseases.



Qsam Biosciences is an OTC company with loads of potential in that space. The Austin, Texas-based company trades under the symbol QSAM.



QSAM uses a unique technology CycloSam (Samarium-153 DOTMP) to clinically stage bone targeting radiopharmaceutical which is developed by IsoTherapeutics Group LLC.



Cyclosam is an already FDA-approved drug.



IsoTherapeutics has recently developed Quadramet which is used for pain palliation.



In short, investors need to know that the combination of radioactive isotope and the chelant DOTMP provides a radioactive dose to the sites of mineral turnover such as bone cancers.



QSAM has a market capitalization of $9.30 million and there are currently 1.69 million shares outstanding.



The 52-week high is $16/share and the 52-week low is $3.50/share.



QSAM currently trades at $5.50.



If you want to learn more about this fascinating targeted therapeutic radiopharmaceutical company, visit QSAM’s web site at www.qsambio.com.